141 related articles for article (PubMed ID: 23442794)
1. MicroRNAs and the cellular response to rapamycin: potential role in diagnosis and therapy.
Totary-Jain H; Marks AR
Cell Cycle; 2013 Mar; 12(6):861-2. PubMed ID: 23442794
[No Abstract] [Full Text] [Related]
2. From node to pathway blockade: lessons learned from targeting mammalian target of rapamycin.
Hidalgo M
J Clin Oncol; 2012 Jan; 30(1):85-7. PubMed ID: 22067403
[No Abstract] [Full Text] [Related]
3. The Enigma of Rapamycin Dosage.
Mukhopadhyay S; Frias MA; Chatterjee A; Yellen P; Foster DA
Mol Cancer Ther; 2016 Mar; 15(3):347-53. PubMed ID: 26916116
[TBL] [Abstract][Full Text] [Related]
4. Reprogramming of the microRNA transcriptome mediates resistance to rapamycin.
Totary-Jain H; Sanoudou D; Ben-Dov IZ; Dautriche CN; Guarnieri P; Marx SO; Tuschl T; Marks AR
J Biol Chem; 2013 Mar; 288(9):6034-44. PubMed ID: 23300087
[TBL] [Abstract][Full Text] [Related]
5. Rapamycin resistance is linked to defective regulation of Skp2.
Totary-Jain H; Sanoudou D; Dautriche CN; Schneller H; Zambrana L; Marks AR
Cancer Res; 2012 Apr; 72(7):1836-43. PubMed ID: 22311674
[TBL] [Abstract][Full Text] [Related]
6. Mammalian target of rapamycin as a target in hematological malignancies.
Kelly KR; Rowe JH; Padmanabhan S; Nawrocki ST; Carew JS
Target Oncol; 2011 Mar; 6(1):53-61. PubMed ID: 21499765
[TBL] [Abstract][Full Text] [Related]
7. Mechanistic target of rapamycin small interfering RNA and rapamycin synergistically inhibit tumour growth in a mouse xenograft model of human oesophageal carcinoma.
Sun MM; Zhang MZ; Chen Y; Li SL; Zhang W; Ya GW; Chen KS
J Int Med Res; 2012; 40(5):1636-43. PubMed ID: 23206445
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of mTOR inhibitor resistance in cancer therapy.
Carew JS; Kelly KR; Nawrocki ST
Target Oncol; 2011 Mar; 6(1):17-27. PubMed ID: 21547705
[TBL] [Abstract][Full Text] [Related]
9. Are we ready to move away from nature?: the rapamycin story.
Mita M; Mita A
Target Oncol; 2011 Jun; 6(2):63-4. PubMed ID: 21674158
[No Abstract] [Full Text] [Related]
10. Rapamycin-induced autophagy plays a pro-survival role by enhancing up-regulation of intracellular ferritin expression in acute lymphoblastic leukemia.
Gong Y; Wu J; Yang R; Zhang L; Ma Z
Exp Oncol; 2020 Mar; 42(1):11-15. PubMed ID: 32231197
[TBL] [Abstract][Full Text] [Related]
11. mTOR-dependent regulation of PHLPP expression controls the rapamycin sensitivity in cancer cells.
Liu J; Stevens PD; Gao T
J Biol Chem; 2011 Feb; 286(8):6510-20. PubMed ID: 21177869
[TBL] [Abstract][Full Text] [Related]
12. Compensatory Increase of Transglutaminase 2 Is Responsible for Resistance to mTOR Inhibitor Treatment.
Cao J; Huang W
PLoS One; 2016; 11(2):e0149388. PubMed ID: 26872016
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of activation of AMPK and upregulation of OGG1 by rapamycin in cancer cells.
Habib SL
Oncotarget; 2011 Dec; 2(12):958-9. PubMed ID: 22193713
[No Abstract] [Full Text] [Related]
14. Rapamycin Impairs Antitumor CD8+ T-cell Responses and Vaccine-Induced Tumor Eradication.
Chaoul N; Fayolle C; Desrues B; Oberkampf M; Tang A; Ladant D; Leclerc C
Cancer Res; 2015 Aug; 75(16):3279-91. PubMed ID: 26122844
[TBL] [Abstract][Full Text] [Related]
15. Mammalian target of rapamycin (mTOR) Inhibitors.
Dutcher JP
Curr Oncol Rep; 2004 Mar; 6(2):111-5. PubMed ID: 14751088
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous T-cell lymphoma cells are sensitive to rapamycin.
Kremer M; Sliva K; Klemke CD; Schnierle BS
Exp Dermatol; 2010 Sep; 19(9):800-5. PubMed ID: 20629739
[TBL] [Abstract][Full Text] [Related]
17. Protein phosphatase 2A and DNA-dependent protein kinase are involved in mediating rapamycin-induced Akt phosphorylation.
Li Y; Wang X; Yue P; Tao H; Ramalingam SS; Owonikoko TK; Deng X; Wang Y; Fu H; Khuri FR; Sun SY
J Biol Chem; 2013 May; 288(19):13215-24. PubMed ID: 23536185
[TBL] [Abstract][Full Text] [Related]
18. Suppression of miR-19b enhanced the cytotoxic effects of mTOR inhibitors in human neuroblastoma cells.
Chen Y; Tsai YH; Tseng BJ; Pan HY; Tseng SH
J Pediatr Surg; 2016 Nov; 51(11):1818-1825. PubMed ID: 27492819
[TBL] [Abstract][Full Text] [Related]
19. Longevity, aging and rapamycin.
Ehninger D; Neff F; Xie K
Cell Mol Life Sci; 2014 Nov; 71(22):4325-46. PubMed ID: 25015322
[TBL] [Abstract][Full Text] [Related]
20. Rapamycin treatment dose-dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell-cycle-associated CDK1/cyclin axis.
Li A; Fan S; Xu Y; Meng J; Shen X; Mao J; Zhang L; Zhang X; Moeckel G; Wu D; Wu G; Liang C
J Cell Mol Med; 2017 Aug; 21(8):1619-1635. PubMed ID: 28244683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
